We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-13.32%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.5B
AUM Growth
-$255M
Cap. Flow
+$290M
Cap. Flow %
11.6%
Top 10 Hldgs %
45.64%
Holding
89
New
6
Increased
32
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$50.9M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$35.6M
3
RLAY icon
Relay Therapeutics
RLAY
+$34M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$31.1M
5
ARGX icon
argenx
ARGX
+$29.1M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$50.6M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$29.4M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.95M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
26
Lexicon Pharmaceuticals
LXRX
$1.03B
$30M 1.2%
14,356,589
-3,411
-0% -$9.46K
ACIU icon
27
AC Immune
ACIU
$227M
$29.7M 1.19%
7,428,379
+366,000
+5% +$1.58M
STRO icon
28
Sutro Biopharma
STRO
$402M
$28.3M 1.13%
344,795
+252,280
+273% +$24M
VSTM icon
29
Verastem
VSTM
$496M
$28.2M 1.13%
1,664,555
+242,708
+17% +$4.18M
PNT
30
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$26.8M 1.07%
3,367,826
+447,300
+15% +$2.84M
TYRA icon
31
Tyra Biosciences
TYRA
$1.88B
$26.5M 1.06%
2,472,327
+598,995
+32% +$7.11M
ANTX icon
32
AN2 Therapeutics
ANTX
$196M
$24.4M 0.97%
+1,616,665
New +$24.5M
EPIX
33
DELISTED
ESSA Pharma
EPIX
$22.8M 0.91%
3,695,629
+844,168
+30% +$7.42M
OVID icon
34
Ovid Therapeutics
OVID
$420M
$21.5M 0.86%
6,851,051
+220,000
+3% +$692K
GBIO
35
DELISTED
Generation Bio
GBIO
$20.6M 0.82%
280,295
+261,390
+1,383% +$15.1M
IDYA icon
36
IDEAYA Biosciences
IDYA
$3.43B
$17.9M 0.72%
+1,600,559
New +$23.6M
RAIN
37
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$17.9M 0.72%
3,526,729
+568,922
+19% +$4.56M
VIRX
38
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$17.2M 0.69%
3,614,662
+175,718
+5% +$529K
JANX icon
39
Janux Therapeutics
JANX
$924M
$16.4M 0.66%
1,142,340
+125,026
+12% +$2.05M
PVLA
40
Palvella Therapeutics
PVLA
$2.04B
$16.1M 0.65%
66,603
– –
CNTA
41
DELISTED
Centessa Pharmaceuticals
CNTA
$15.7M 0.63%
1,755,545
+1,301,000
+286% +$11.9M
REPL icon
42
Replimune Group
REPL
$876M
$15.7M 0.63%
926,529
– –
CTMX icon
43
CytomX Therapeutics
CTMX
$686M
$15.5M 0.62%
5,803,700
– –
IMA
44
ImageneBio Inc
IMA
$63.6M
$15.3M 0.61%
208,464
+58,600
+39% +$6.23M
WHWK
45
Whitehawk Therapeutics
WHWK
$190M
$14.9M 0.6%
879,085
-20,307
-2% -$389K
NGM
46
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$14.6M 0.58%
955,000
– –
CFRX
47
DELISTED
ContraFect Corporation
CFRX
$14.5M 0.58%
49,654
– –
ALPN
48
DELISTED
Alpine Immune Sciences Inc
ALPN
$14.3M 0.57%
1,589,495
– –
MTEM
49
DELISTED
Molecular Templates, Inc.
MTEM
$14M 0.56%
269,782
+61,142
+29% +$2.7M
CALT
50
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$13.9M 0.56%
750,000
– –
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2022 Portfolio in Review

As of Q1 2022, BVF Inc held 89 positions worth $2.5B, down 9.3% from $2.76B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

BVF Inc deployed $290M of net new capital in Q1 2022, opening 6 new positions and adding to 32 existing holdings. Its largest new stake was iTeos Therapeutics: 1,400,201 shares worth $45.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $50.6M trimmed.

  • BVF Inc's largest Q1 2022 buy was iTeos Therapeutics: 1,400,201 shares worth $45.1M.
  • BVF Inc added most to Relay Therapeutics in Q1 2022, an estimated $34M increase.
  • BVF Inc's biggest Q1 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $50.6M.
  • BVF Inc fully exited Amarin Corp in Q1 2022, selling an estimated $55.5M.
  • BVF Inc's ten largest holdings make up 46% of its $2.5B portfolio in Q1 2022.
  • BVF Inc opened 6 new positions and closed 8 in Q1 2022.
  • BVF Inc's portfolio value fell 9.3% quarter-over-quarter to $2.5B.

Based on BVF Inc's 13F filing for Q1 2022, filed 16 May 2022.